Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Hajime Iizuka, Jiro Uehara, Fujio Otsuka, Yasuhiro Fujisawa, Tatsuya Takenouchi, Taiki Isei, Keiji Iwatsuki, Hiroshi Uchi, Hironobu Ihn, Hironobu Minami, Hideaki Tahara

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitumor activities of nivolumab and explored its predictive correlates in advanced melanoma patients at 11 sites in Japan. Intravenous nivolumab 2 mg/kg was given repeatedly at 3-week intervals to 35 of 37 patients enrolled from December 2011 to May 2012 until they experienced unacceptable toxicity, disease progression, or complete response. Primary endpoint was objective response rate. Serum levels of immune modulators were assessed at multiple time points. As of 21 October 2014, median response duration, median progression-free survival, and median overall survival were 463 days, 169 days, and 18.0 months, respectively. The overall response rate and 1- and 2-year survival rates were 28.6%, 54.3%, and 42.9%, respectively. Thirteen patients remained alive at the end of the observation period and no deaths were drug related. Grade 3-4 drug-related adverse events were observed in 31.4% of patients. Pretreatment serum interferon-γ, and interleukin-6 and -10 levels were significantly higher in the patients with objective tumor responses than in those with tumor progression. In conclusion, giving repeated i.v. nivolumab had potent and durable antitumor effects and a manageable safety profile in advanced melanoma patients, strongly suggesting the usefulness of nivolumab for advanced melanoma and the usefulness of pretreatment serum cytokine profiles as correlates for predicting treatment efficacy.

Original languageEnglish
JournalCancer Science
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Melanoma
Biomarkers
Cytokines
Drug-Related Side Effects and Adverse Reactions
Serum
Interleukin-10
Interferons
Disease-Free Survival
Disease Progression
nivolumab
Immune Sera
Interleukin-6
Neoplasms
Japan
Survival Rate
Immunoglobulin G
Observation
Safety
Survival
Antibodies

Keywords

  • Antibody therapy
  • Biomarker
  • Check-point inhibitor
  • Clinical trial
  • Programmed cell death-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yamazaki, N., Kiyohara, Y., Uhara, H., Iizuka, H., Uehara, J., Otsuka, F., ... Tahara, H. (Accepted/In press). Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Science. https://doi.org/10.1111/cas.13226

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. / Yamazaki, Naoya; Kiyohara, Yoshio; Uhara, Hisashi; Iizuka, Hajime; Uehara, Jiro; Otsuka, Fujio; Fujisawa, Yasuhiro; Takenouchi, Tatsuya; Isei, Taiki; Iwatsuki, Keiji; Uchi, Hiroshi; Ihn, Hironobu; Minami, Hironobu; Tahara, Hideaki.

In: Cancer Science, 2017.

Research output: Contribution to journalArticle

Yamazaki, N, Kiyohara, Y, Uhara, H, Iizuka, H, Uehara, J, Otsuka, F, Fujisawa, Y, Takenouchi, T, Isei, T, Iwatsuki, K, Uchi, H, Ihn, H, Minami, H & Tahara, H 2017, 'Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma', Cancer Science. https://doi.org/10.1111/cas.13226
Yamazaki, Naoya ; Kiyohara, Yoshio ; Uhara, Hisashi ; Iizuka, Hajime ; Uehara, Jiro ; Otsuka, Fujio ; Fujisawa, Yasuhiro ; Takenouchi, Tatsuya ; Isei, Taiki ; Iwatsuki, Keiji ; Uchi, Hiroshi ; Ihn, Hironobu ; Minami, Hironobu ; Tahara, Hideaki. / Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. In: Cancer Science. 2017.
@article{ef19009663434eaeb1292caa095a18a8,
title = "Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma",
abstract = "Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitumor activities of nivolumab and explored its predictive correlates in advanced melanoma patients at 11 sites in Japan. Intravenous nivolumab 2 mg/kg was given repeatedly at 3-week intervals to 35 of 37 patients enrolled from December 2011 to May 2012 until they experienced unacceptable toxicity, disease progression, or complete response. Primary endpoint was objective response rate. Serum levels of immune modulators were assessed at multiple time points. As of 21 October 2014, median response duration, median progression-free survival, and median overall survival were 463 days, 169 days, and 18.0 months, respectively. The overall response rate and 1- and 2-year survival rates were 28.6{\%}, 54.3{\%}, and 42.9{\%}, respectively. Thirteen patients remained alive at the end of the observation period and no deaths were drug related. Grade 3-4 drug-related adverse events were observed in 31.4{\%} of patients. Pretreatment serum interferon-γ, and interleukin-6 and -10 levels were significantly higher in the patients with objective tumor responses than in those with tumor progression. In conclusion, giving repeated i.v. nivolumab had potent and durable antitumor effects and a manageable safety profile in advanced melanoma patients, strongly suggesting the usefulness of nivolumab for advanced melanoma and the usefulness of pretreatment serum cytokine profiles as correlates for predicting treatment efficacy.",
keywords = "Antibody therapy, Biomarker, Check-point inhibitor, Clinical trial, Programmed cell death-1",
author = "Naoya Yamazaki and Yoshio Kiyohara and Hisashi Uhara and Hajime Iizuka and Jiro Uehara and Fujio Otsuka and Yasuhiro Fujisawa and Tatsuya Takenouchi and Taiki Isei and Keiji Iwatsuki and Hiroshi Uchi and Hironobu Ihn and Hironobu Minami and Hideaki Tahara",
year = "2017",
doi = "10.1111/cas.13226",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

AU - Yamazaki, Naoya

AU - Kiyohara, Yoshio

AU - Uhara, Hisashi

AU - Iizuka, Hajime

AU - Uehara, Jiro

AU - Otsuka, Fujio

AU - Fujisawa, Yasuhiro

AU - Takenouchi, Tatsuya

AU - Isei, Taiki

AU - Iwatsuki, Keiji

AU - Uchi, Hiroshi

AU - Ihn, Hironobu

AU - Minami, Hironobu

AU - Tahara, Hideaki

PY - 2017

Y1 - 2017

N2 - Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitumor activities of nivolumab and explored its predictive correlates in advanced melanoma patients at 11 sites in Japan. Intravenous nivolumab 2 mg/kg was given repeatedly at 3-week intervals to 35 of 37 patients enrolled from December 2011 to May 2012 until they experienced unacceptable toxicity, disease progression, or complete response. Primary endpoint was objective response rate. Serum levels of immune modulators were assessed at multiple time points. As of 21 October 2014, median response duration, median progression-free survival, and median overall survival were 463 days, 169 days, and 18.0 months, respectively. The overall response rate and 1- and 2-year survival rates were 28.6%, 54.3%, and 42.9%, respectively. Thirteen patients remained alive at the end of the observation period and no deaths were drug related. Grade 3-4 drug-related adverse events were observed in 31.4% of patients. Pretreatment serum interferon-γ, and interleukin-6 and -10 levels were significantly higher in the patients with objective tumor responses than in those with tumor progression. In conclusion, giving repeated i.v. nivolumab had potent and durable antitumor effects and a manageable safety profile in advanced melanoma patients, strongly suggesting the usefulness of nivolumab for advanced melanoma and the usefulness of pretreatment serum cytokine profiles as correlates for predicting treatment efficacy.

AB - Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitumor activities of nivolumab and explored its predictive correlates in advanced melanoma patients at 11 sites in Japan. Intravenous nivolumab 2 mg/kg was given repeatedly at 3-week intervals to 35 of 37 patients enrolled from December 2011 to May 2012 until they experienced unacceptable toxicity, disease progression, or complete response. Primary endpoint was objective response rate. Serum levels of immune modulators were assessed at multiple time points. As of 21 October 2014, median response duration, median progression-free survival, and median overall survival were 463 days, 169 days, and 18.0 months, respectively. The overall response rate and 1- and 2-year survival rates were 28.6%, 54.3%, and 42.9%, respectively. Thirteen patients remained alive at the end of the observation period and no deaths were drug related. Grade 3-4 drug-related adverse events were observed in 31.4% of patients. Pretreatment serum interferon-γ, and interleukin-6 and -10 levels were significantly higher in the patients with objective tumor responses than in those with tumor progression. In conclusion, giving repeated i.v. nivolumab had potent and durable antitumor effects and a manageable safety profile in advanced melanoma patients, strongly suggesting the usefulness of nivolumab for advanced melanoma and the usefulness of pretreatment serum cytokine profiles as correlates for predicting treatment efficacy.

KW - Antibody therapy

KW - Biomarker

KW - Check-point inhibitor

KW - Clinical trial

KW - Programmed cell death-1

UR - http://www.scopus.com/inward/record.url?scp=85018934527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018934527&partnerID=8YFLogxK

U2 - 10.1111/cas.13226

DO - 10.1111/cas.13226

M3 - Article

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -